🔒 Private Access

Please enter the password to view the LLY Research Pipeline Dashboard.

Incorrect password. Please try again.

Eli Lilly Research Pipeline

Interactive Drug Development Tracker · NYSE: LLY · Updated May 25, 2026
FY2025 Revenue by Product (USD)
Mounjaro
$23.0B
T2D · GIP/GLP-1
▲ 94% YoY
Zepbound
$13.5B
Obesity · Tirzepatide
▲ 285% YoY
Verzenio
$5.7B
Breast Cancer · CDK4/6
▲ 8% YoY
Jardiance
$3.2B
T2D/HF · SGLT2
▲ 15% YoY
Taltz
$3.5B
Psoriasis · IL-17A
▲ 18% YoY
Other Key Products
$16.3B
Trulicity, Humalog, Ebglyss, Omvoh, Kisunla, Jaypirca, Inluriyo
▲ 12%
Total Revenue
$65.2B
FY2025 · +45% YoY
2026E: $82–85B ↑
2026 Guidance (Non-GAAP) ↑ Raised Apr 30
Revenue
$82–85B
+28% midpoint · Q1 +56%
EPS
$35.50–37.00
+50% midpoint · Q1 $8.55 (beat)
Perf. Margin
47–48.5%
Foundayo™ US
✓ Launched
Apr 9, 2026 · $25–149/mo
FDA Approval Timeline — Near-Term Catalysts
Inluriyo
Oct 2025
ER+/HER2− mBC
Jaypirca
Q4 2025
Full approval + CLL/SLL
Foundayo™
Apr 9, 2026 ✓
US Launch · First Non-Peptide Oral GLP-1
Efsitora Alfa
2026
Weekly insulin T2D
Pirtobrutinib 1L
2026
1L CLL filed US/EU
Tirzepatide CV
2026
SURPASS-CVOT filed US
Retatrutide
Late 2026
NDA post TRIUMPH 1/2/3
6
Reg Review / Filed
36
Phase 3 Programs
25+
Phase 1/2
34
Discovery
Disclaimer: For informational purposes only — not investment advice. Updated May 25, 2026. Source: investor.lilly.com (earnings, presentations, press releases), SEC filings, NEJM, Lancet, clinicaltrials.gov.